Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies
Program: Scientific Workshops
Session: CAR-19 Resistance in Acute Lymphoblastic Leukemia
Program: Scientific Workshops
Session: CAR-19 Resistance in Acute Lymphoblastic Leukemia
Friday, December 6, 2024, 4:18 PM-4:54 PM
Disclosures: Alizadeh: BMS: Research Funding; Pharmacyclics: Consultancy; Forty Seven: Other: stock; Roche: Consultancy; Gilead: Consultancy; Foresight: Consultancy, Other: Scientific Co-founder; CiberMed: Consultancy, Other: Scientific Co-founder; CARGO Therapeutics: Divested equity in a private or publicly-traded company in the past 24 months; ADC Therapeutics: Consultancy; Adaptive Biosciences: Consultancy.
See more of: CAR-19 Resistance in Acute Lymphoblastic Leukemia
See more of: Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies
See more of: Scientific Workshops
See more of: Scientific Workshop on Understanding and Overcoming Tumor-intrinsic Resistance to CAR-T Therapies for Lymphoid Malignancies
See more of: Scientific Workshops
Previous Presentation
|
Next Presentation >>